Vanda Submits NDA For Antipsychotic Iloperidone
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm says if schizophrenia treatment is approved, a favorable safety profile will differentiate the product from competitors.
You may also be interested in...
Biomarkers for Psychiatric Drugs: Outlier or Opportunity?
A handful of companies are pursuing predictive genetic tests for evaluating psychiatric drugs. The need is apparent, and an early success could trigger a rapid shift in thinking about the sustainability of building a business around biomarkers in a therapeutic area sometimes considered the least likely to benefit near term from their development. That said, firms in this area--and elsewhere--must be wary of leaning too heavily on pharma companies as supportive partners.
Encouraging Phase III Data Reported For Vanda’s Schizophrenia Candidate
Iloperidone could have a potential tolerability advantage over Pfizer’s Geodon.
Encouraging Phase III Data Reported For Vanda’s Schizophrenia Candidate
Iloperidone could have a potential tolerability advantage over Pfizer’s Geodon.